Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(88 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(79 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(26 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1370 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
SYR127063
CAS:<p>SYR127063 (BDBM-92454) (BDBM92454) is a potent and selective HER2 inhibitor, binds to HER2 in a reactive conformation.</p>Fórmula:C23H20ClF3N4O3Pureza:98.57%Cor e Forma:SolidPeso molecular:492.88Pexmetinib
CAS:<p>Pexmetinib (ARRY-614) is an orally bioavailable dual p38 MAPK/Tie-2 inhibitor.Cost-effective and quality-assured.</p>Fórmula:C31H33FN6O3Pureza:99.07% - 99.66%Cor e Forma:SolidPeso molecular:556.63Crenolanib
CAS:<p>Crenolanib (ARO 002) is an orally bioavailable type III tyrosine kinases inhibitor of PDGFRα/β and FLT3 (IC50s: 11, 3.2, and 4 nM).</p>Fórmula:C26H29N5O2Pureza:98.40% - 99.73%Cor e Forma:SolidPeso molecular:443.54AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Cor e Forma:Yellow SolidPeso molecular:294.3Bemcentinib
CAS:<p>Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.</p>Fórmula:C30H34N8Pureza:97% - 99.8%Cor e Forma:SolidPeso molecular:506.64Vorolanib
CAS:<p>Vorolanib (X-82) is an orally active VEGFR/PDGFR dual inhibitor.</p>Fórmula:C23H26FN5O3Pureza:97.35%Cor e Forma:SolidPeso molecular:439.48Chrysophanol
CAS:<p>Chrysophanol (Turkey Rhubarb) is an EGFR/mTOR pathway inhibitor, which can be found in rhubarb, and sorrel.</p>Fórmula:C15H10O4Pureza:99.44% - 99.91%Cor e Forma:Physical Description Golden Yellow Plates Or Brown Powder Melting Point 196°CPeso molecular:254.24ZM 306416
CAS:<p>ZM 306416 (CB 676475), a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM).</p>Fórmula:C16H13ClFN3O2Pureza:99.37% - ≥95%Cor e Forma:SolidPeso molecular:333.74Fruquintinib
CAS:<p>Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-</p>Fórmula:C21H19N3O5Pureza:98.84% - 99.89%Cor e Forma:SolidPeso molecular:393.39Vatalanib free base
CAS:<p>Vatalanib is a VEGFR2/KDR inhibitor (IC50: 37 nM).</p>Fórmula:C20H15ClN4Pureza:99.52%Cor e Forma:SolidPeso molecular:346.81AMG-47a
CAS:<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Fórmula:C29H28F3N5O2Pureza:98%Cor e Forma:SolidPeso molecular:535.56Toceranib Phosphate
CAS:<p>Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family.</p>Fórmula:C22H28FN4O6PPureza:98.56%Cor e Forma:SolidPeso molecular:494.45ANA-12
CAS:<p>ANA-12 is a potent and selective TrkB antagonist with anxiolytic and antidepressant activity in mice.</p>Fórmula:C22H21N3O3SPureza:99.28% - 99.87%Cor e Forma:SolidPeso molecular:407.49Oritinib mesylate
CAS:<p>Oritinib mesylate (SH-1028), an oral pyrimidine EGFR blocker with 18 nM IC50, targets both sensitive and T790M resistant mutations.</p>Fórmula:C32H41N7O5SCor e Forma:SolidPeso molecular:635.78Fisogatinib
CAS:<p>Fisogatinib (BLU-554) is a highly potent, selective, and orally active FGFR4 inhibitor.Cost-effective and quality-assured.</p>Fórmula:C24H24Cl2N4O4Pureza:99.27% - ≥95%Cor e Forma:SolidPeso molecular:503.38LOXO-195
CAS:<p>(6RS)-LOXO-195 (BAY 2731954) is a potent and selective Trk tyrosine kinase inhibitor.</p>Fórmula:C20H21FN6OPureza:99.54%Cor e Forma:SolidPeso molecular:380.42BIIB068
CAS:<p>BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.</p>Fórmula:C23H29N7O2Pureza:97.98%Cor e Forma:SolidPeso molecular:435.52SB 525334
CAS:<p>SB-525334 is a potent and selective inhibitor of the TGF-β1R and ALK5 (IC50: 14.3 nM).</p>Fórmula:C21H21N5Pureza:98.39% - ≥95%Cor e Forma:SolidPeso molecular:343.42Insulin(cattle)
CAS:<p>Insulin(cattle) is a peptide hormone that promotes glycogen synthesis. Insulin) has hypoglycemic activity. Cost-effective and quality-assured.</p>Fórmula:C254H377N65O75S6Pureza:98%Cor e Forma:SolidPeso molecular:5733.49PD-166866
CAS:<p>PD-166866 is a selective FGFR tyrosine kinase inhibitor.</p>Fórmula:C20H24N6O3Pureza:98.29%Cor e Forma:SolidPeso molecular:396.44Decernotinib
CAS:<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Fórmula:C18H19F3N6OPureza:99.28% - >99.99%Cor e Forma:SolidPeso molecular:392.38Theliatinib tartrate
CAS:<p>Theliatinib: oral EGFR blocker, Ki 0.05 nM, IC50 3 nM (wild-type), 22 nM (T790M/L858R), >50x kinase selectivity.</p>Fórmula:C29H32N6O8Cor e Forma:SolidPeso molecular:592.6Bafetinib
CAS:<p>Bafetinib (INNO-406): Dual Bcr-Abl/Lyn inhibitor; IC50: 5.8/19 nM; ineffective against T315I mutant, less on c-Kit/PDGFR.</p>Fórmula:C30H31F3N8OPureza:94.16% - 99.68%Cor e Forma:SolidPeso molecular:576.62XL 999
CAS:<p>Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor（KDR, Flt-1, FGFR1 and PDGFRα with IC50s of 4nM, 20nM, 4nM, 2 nM ,respectively）</p>Fórmula:C26H28FN5OPureza:98.24% - 99.55%Cor e Forma:SolidPeso molecular:445.53Su1498
CAS:<p>Su1498 (Tyrphostin SU 1498) is a selective inhibitor of the VEGF receptor 2, having negligible activity at several other serine/threonine and tyrosine kinases.</p>Fórmula:C25H30N2O2Pureza:99.54%Cor e Forma:SolidPeso molecular:390.52ZAP-180013
CAS:<p>ZAP-180013 is an inhibitor of zeta-chain-associated protein kinase 70 (ZAP70,IC50 : 1.8 μM).</p>Fórmula:C19H17Cl2N3O4SPureza:98.89%Cor e Forma:SolidPeso molecular:454.33G5-7
CAS:<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Fórmula:C22H19F2NO3Pureza:97.3%Cor e Forma:SolidPeso molecular:383.39AG-494
CAS:<p>AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase.</p>Fórmula:C16H12N2O3Pureza:98.69%Cor e Forma:SolidPeso molecular:280.28LDN-212854
CAS:<p>LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors.</p>Fórmula:C25H22N6Pureza:98% - 98.71%Cor e Forma:SolidPeso molecular:406.48DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Fórmula:C41H42FN5O7Pureza:99.75%Cor e Forma:SolidPeso molecular:735.8(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Fórmula:C23H24N4OPureza:97.75% - 99.92%Cor e Forma:SolidPeso molecular:372.46Neratinib
CAS:<p>Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59/92 nM), respectively.</p>Fórmula:C30H29ClN6O3Pureza:96.17% - 99.85%Cor e Forma:SolidPeso molecular:557.04Ceritinib dihydrochloride
CAS:<p>Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable, ATP-competitive inhibitor of ALK tyrosine kinase with antitumour effect.</p>Fórmula:C28H38Cl3N5O3SPureza:99.85% - 99.99%Cor e Forma:SolidPeso molecular:631.06Osimertinib mesylate
CAS:<p>Osimertinib mesylate (AZD-9291 mesylate) is an EGFR third-generation inhibitor. Osimertinib mesylate has antitumor activity. Cost-effective and quality-assured.</p>Fórmula:C29H37N7O5SPureza:99.46% - >99.99%Cor e Forma:SolidPeso molecular:595.71BFH772
CAS:<p>BFH772, a BAW2881 analogue, selectively inhibits VEGFR2 (IC50: 3 nM) and blocks RET, PDGFR, KIT phosphorylation (IC50: 30-160 nM).</p>Fórmula:C23H16F3N3O3Pureza:97.71% - 99.36%Cor e Forma:SolidPeso molecular:439.39Derazantinib
CAS:<p>Derazantinib (ARQ-087) is a potent, ATP-competitive, orally active tyrosine kinase inhibitor.Cost-effective and quality-assured.</p>Fórmula:C29H29FN4OPureza:99.71%Cor e Forma:SolidPeso molecular:468.57Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Fórmula:C18H22N4O2Pureza:98.67% - 99.4%Cor e Forma:SolidPeso molecular:326.39AG 1406
CAS:<p>AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2.</p>Fórmula:C16H18N2OPureza:98.12%Cor e Forma:SolidPeso molecular:254.33AG-1478
CAS:<p>AG-1478 (NSC-693255) (Tyrphostin AG-1478) is a selective EGFR inhibitor.</p>Fórmula:C16H14ClN3O2Pureza:99.03% - 99.71%Cor e Forma:SolidPeso molecular:315.75Saracatinib
CAS:<p>Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.</p>Fórmula:C27H32ClN5O5Pureza:98% - 99.63%Cor e Forma:SolidPeso molecular:542.03BIBF0775
CAS:<p>BIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM).</p>Fórmula:C31H34N4O2Pureza:99.45% - 99.79%Cor e Forma:SolidPeso molecular:494.63AG-13958
CAS:<p>AG-13958 (AG-013958) (AG-013958), a potent VEGFR tyrosine kinase inhibitor, for the treatment of age-related macular degeneration.</p>Fórmula:C26H22FN7OPureza:99.4%Cor e Forma:SolidPeso molecular:467.5PF-6274484
CAS:<p>PF-6274484 is an EGFR inhibitor with Ki values of 0.14 and 0.18 nM for EGFR-L858R/T790M and WT-EGFR, respectively.</p>Fórmula:C18H14ClFN4O2Pureza:97.71%Cor e Forma:SolidPeso molecular:372.78KI8751
CAS:<p>KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.</p>Fórmula:C24H18F3N3O4Pureza:99.22% - 99.9%Cor e Forma:SolidPeso molecular:469.41CYC-116
CAS:<p>CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active</p>Fórmula:C18H20N6OSPureza:97.36% - 97.59%Cor e Forma:SolidPeso molecular:368.46RG13022
CAS:<p>RG13022 (Tyrphostin RG13022) is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM).</p>Fórmula:C16H14N2O2Pureza:98.38%Cor e Forma:SolidPeso molecular:266.29Olafertinib
CAS:<p>Olafertinib (RX-518) is a novel mutant-selective, irreversible, orally available EGFR inhibitor. It can overcome T790M-mediated resistance in NSCLC.</p>Fórmula:C29H28F2N6O2Pureza:98.62% - 99.706%Cor e Forma:SolidPeso molecular:530.57PD173955
CAS:<p>PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and</p>Fórmula:C21H16Cl2N4OSPureza:98.52% - 98.99%Cor e Forma:SolidPeso molecular:443.35Scutellarein
CAS:<p>Scutellarein (6-Hydroxyapigenin) reduces inflammatory responses by inhibiting Src kinase activity.</p>Fórmula:C15H10O6Pureza:98.02% - 99.63%Cor e Forma:SolidPeso molecular:286.24AST 487
CAS:<p>AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.</p>Fórmula:C26H30F3N7O2Pureza:98.17% - 99.56%Cor e Forma:SolidPeso molecular:529.56PD-089828
CAS:<p>PD 089828 inhibits FGFR1, PDGFRβ, EGFR (IC50s: 0.15-5.47 μM), and c-Src (IC50: 0.18 μM).</p>Fórmula:C18H18Cl2N6OPureza:97.39%Cor e Forma:SolidPeso molecular:405.28BPR1J-097
CAS:<p>BPR1J-097) is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).</p>Fórmula:C27H28N6O3SPureza:99.3%Cor e Forma:SolidPeso molecular:516.61Nazartinib
CAS:<p>Nazartinib (EGF816) (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (</p>Fórmula:C26H31ClN6O2Pureza:98.63% - ≥95%Cor e Forma:Solid PowderPeso molecular:495.02UNC2025
CAS:<p>UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor.</p>Fórmula:C28H40N6OPureza:99.53% - 99.74%Cor e Forma:SolidPeso molecular:476.66NT157
CAS:<p>NT157, a small tyrphostin, inhibits IRS, IGF-1R, and STAT3 in TME, reducing cancer cell survival.</p>Fórmula:C16H14BrNO5SPureza:99.64%Cor e Forma:SolidPeso molecular:412.26ENMD-2076
CAS:<p>ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.</p>Fórmula:C21H25N7Pureza:97.63% - ≥95%Cor e Forma:SolidPeso molecular:375.47Motesanib
CAS:<p>Motesanib (AMG 706) orally blocks VEGFR, PDGFR, Kit, Ret; curbing angiogenesis and cancer cell growth.</p>Fórmula:C22H23N5OPureza:98% - 99.09%Cor e Forma:SolidPeso molecular:373.45hVEGF-IN-1
CAS:<p>hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.</p>Fórmula:C34H43N7O2Pureza:99.76% - >99.99%Cor e Forma:SolidPeso molecular:581.75KHS101 hydrochloride
CAS:<p>KHS101 is a TACC3 inhibitor and can selectively induce a neuronal differentiation phenotype.</p>Fórmula:C18H22ClN5SPureza:99.6%Cor e Forma:SolidPeso molecular:375.92S49076
CAS:<p>S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.</p>Fórmula:C22H22N4O4SPureza:95.35% - 97.4%Cor e Forma:SolidPeso molecular:438.5PD153035
CAS:<p>PD153035 (NSC-669364) hydrochloride is an effective and selective inhibitor of EGFR (Ki/IC50: 5.2/29 pM, in cell-free assays); little inhibitory against FGFR,</p>Fórmula:C16H14BrN3O2Pureza:98.47% - 99.29%Cor e Forma:SolidPeso molecular:360.21SU4312
CAS:<p>SU-4312 (DMBI) inhibits VEGFR & PDGFR (IC50: 0.8, 19.4 μM) and shields neurons from MPP(+)-induced damage by blocking nNOS.</p>Fórmula:C17H16N2OPureza:>99.99%Cor e Forma:SolidPeso molecular:264.32Tuxobertinib
CAS:<p>Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.</p>Fórmula:C29H29ClN6O4Pureza:99.22%Cor e Forma:SolidPeso molecular:561.03Sitravatinib
CAS:<p>Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and</p>Fórmula:C33H29F2N5O4SPureza:98.9% - 99.85%Cor e Forma:SolidPeso molecular:629.68ODM-203
CAS:<p>ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity</p>Fórmula:C26H21F2N5O2SPureza:99.85%Cor e Forma:SolidPeso molecular:505.54Afatinib
CAS:<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Fórmula:C24H25ClFN5O3Pureza:98.56% - 99.9%Cor e Forma:Off-White SolidPeso molecular:485.94PRT-060318
CAS:<p>PRT-060318 (P142-76) is a novel selective inhibitor of the Syk tyrosine kinase, as an approach to HIT treatment.</p>Fórmula:C18H24N6OPureza:99.98%Cor e Forma:SolidPeso molecular:340.42DDR1-IN-2
CAS:<p>DDR1-IN-2 (DDR1 inhibitor 7rh) (DDR1 inhibitor 7rh) is a potent, selective, ATP-competitive Discoidin domain receptor 1 (DDR1) inhibitor (IC50: 6.8 nM in cell-</p>Fórmula:C30H29F3N6OPureza:97.51%Cor e Forma:SolidPeso molecular:546.59LDN-192960
CAS:<p>LDN-192960 is a potent inhibitor of Haspin and DYRK2 (IC50s: 10 nM and 48 nM).</p>Fórmula:C18H20N2O2SPureza:98.01% - 99.51%Cor e Forma:SolidPeso molecular:328.43SU14813
CAS:<p>SU14813: inhibits multiple kinases (VEGFR2, VEGFR1, PDGFRβ, KIT) with IC50s of 50, 2, 4, 15 nM; antiangiogenic and antitumor.</p>Fórmula:C23H27FN4O4Pureza:98.13%Cor e Forma:SolidPeso molecular:442.48Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Fórmula:C23H25ClFN7OPureza:99.33% - 99.86%Cor e Forma:SolidPeso molecular:469.94zanubrutinib
CAS:<p>Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).</p>Fórmula:C27H29N5O3Pureza:98.42% - 99.76%Cor e Forma:SolidPeso molecular:471.55Belizatinib
CAS:<p>Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.</p>Fórmula:C33H44FN5O3Pureza:99.33% - 99.44%Cor e Forma:SolidPeso molecular:577.73Ningetinib Tosylate
CAS:<p>Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Fórmula:C38H37FN4O8SPureza:99.93%Cor e Forma:SolidPeso molecular:728.79AIM-100
CAS:<p>AIM-100 is a Ack1 inhibitor (IC50: 24 nM).</p>Fórmula:C23H21N3O2Pureza:98.91%Cor e Forma:SolidPeso molecular:371.43BBT594
CAS:<p>BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.</p>Fórmula:C28H30F3N7O3Pureza:99.57%Cor e Forma:SolidPeso molecular:569.58Epidermal Growth Factor
CAS:<p>EGF binds EGFR, promotes cell growth & heals diabetic foot ulcers.</p>Fórmula:C270H401N73O83S7Pureza:97.17%Cor e Forma:SolidPeso molecular:6222NVP-BVU972
CAS:<p>NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.</p>Fórmula:C20H16N6Pureza:97.24% - >99.99%Cor e Forma:SolidPeso molecular:340.38EAI045
CAS:<p>EAI045, an allosteric inhibitor, targets towards drug-resistant EGFR mutants but avoids the wild-type receptor.</p>Fórmula:C19H14FN3O3SPureza:98.00% - 99.12%Cor e Forma:SolidPeso molecular:383.4Ibrutinib deacryloylpiperidine
CAS:<p>Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.</p>Fórmula:C17H13N5OPureza:99.47%Cor e Forma:SolidPeso molecular:303.32NRC-2694 hydrochloride
CAS:<p>NRC-2694 hydrochloride is an epidermal growth factor receptor (EGFR) antagonist potentially for the treatment of solid tumors.</p>Fórmula:C24H27ClN4O3Cor e Forma:SolidPeso molecular:454.95CUDC-101
CAS:<p>CUDC-101 is a potent inhibitor of HDAC, EGFR and HER2 with IC50s of 4.4, 2.4 and 15.7 nM, respectively.</p>Fórmula:C24H26N4O4Pureza:95.76% - 99.17%Cor e Forma:SolidPeso molecular:434.49Oclacitinib maleate
CAS:<p>Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.</p>Fórmula:C15H23N5O2S·C4H4O4Pureza:99.17%Cor e Forma:SolidPeso molecular:453.51CP-380736
CAS:<p>CP-380736 (PF-00520893) inhibits EGFR, a kinase key in cancer-signaling pathways like MAPK, JNK, and Akt.</p>Fórmula:C14H18N2O5Pureza:99.68%Cor e Forma:White To Off-White SolidPeso molecular:294.3Mobocertinib
CAS:<p>Mobocertinib (tak788) is a potent inhibitor of epidermal growth factor receptor (EGFR) and an antineoplastic agent</p>Fórmula:C32H39N7O4Pureza:99.47% - 99.97%Cor e Forma:SolidPeso molecular:585.7Gefitinib-based PROTAC 3
CAS:<p>Gefitinib-PROTAC 3 degrades EGFR in cancer cells; DC50s: 11.7 nM (HCC827) and 22.3 nM (H3255).</p>Fórmula:C47H57ClFN7O8SPureza:97.29% - 98.25%Cor e Forma:SolidPeso molecular:934.51(Rac)-IBT6A
CAS:<p>(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.</p>Fórmula:C22H22N6OPureza:99.24%Cor e Forma:SolidPeso molecular:386.45WHI-P258
CAS:<p>WHI-P258, a weak JAK3 inhibitor, is used as a negative control in drug development.</p>Fórmula:C16H15N3O2Pureza:99.66% - 99.92%Cor e Forma:SolidPeso molecular:281.31Repotrectinib
CAS:<p>Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01/5.3/1.08/1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.</p>Fórmula:C18H18FN5O2Pureza:99.92% - >99.99%Cor e Forma:SolidPeso molecular:355.37squarunkinA
CAS:<p>squarunkinA is a novel modulator of the UNC119-Cargo Interaction, potently and selectively inhibiting the binding of a myristoylated peptide representing the N-</p>Fórmula:C25H32F3N5O4Pureza:99.29%Cor e Forma:SolidPeso molecular:523.55Malantide acetate(86555-35-3 free base)
<p>Malantide acetate is a dodecapeptide phosphorylated by cyclic AMP-dependent protein kinase (PKA), and increases PKA activity.Malantide is a synthetic peptide</p>Fórmula:C74H128N22O23Pureza:>99.99%Cor e Forma:SolidPeso molecular:1693.97R-268712
CAS:<p>R-268712 is a potent ALK5 inhibitor with a 2.5 nM IC50, also targeting TGF-β type I receptor orally.</p>Fórmula:C20H18FN5OPureza:99.61%Cor e Forma:SolidPeso molecular:363.39MSDC 0160
CAS:<p>MSDC 0160 (CAY10415) is a prototype mTOT-modulating insulin sensitizer being used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease.</p>Fórmula:C19H18N2O4SPureza:98.11% - 99.53%Cor e Forma:SolidPeso molecular:370.42UNC2541
CAS:<p>UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor.</p>Fórmula:C24H34FN7O2Pureza:98.33%Cor e Forma:SolidPeso molecular:471.57Derazantinib dihydrochloride
CAS:<p>Derazantinib, a multi-kinase inhibitor targeting FGFR, benefits FGFR2-positive iCCA; its dihydrochloride form is a salt variant.</p>Fórmula:C29H31Cl2FN4OCor e Forma:SolidPeso molecular:541.49Almonertinib
CAS:<p>Almonertinib (HS-10296) is an inhibitor of EGFR activation mutation and tolerant mutation of EGFR T790M, which has only limited activity against wild-type EGFR.</p>Fórmula:C30H35N7O2Pureza:99.99%Cor e Forma:SolidPeso molecular:525.64PKI 14-22 amide, myristoylated Acetate
<p>PKI 14-22 amide, myristoylated Acetate inhibit cAMP-dependent protein kinase (PKA) and blocks hyperalgesia produced by spinal administration of 8-bromo-cAMP. </p>Fórmula:C55H104N20O14Pureza:96.34%Cor e Forma:SolidPeso molecular:1269.54SU5205
CAS:<p>SU5205 is a VEGFR2 inhibitor.</p>Fórmula:C15H10FNOPureza:99.62% - 99.67%Cor e Forma:SolidPeso molecular:239.24WZ8040
CAS:<p>WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).</p>Fórmula:C24H25ClN6OSPureza:97.42% - 99.785%Cor e Forma:SolidPeso molecular:481.01Merestinib
CAS:<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Fórmula:C30H22F2N6O3Pureza:95% - 99.71%Cor e Forma:SolidPeso molecular:552.53
